YKL-40与前列腺癌临床分期、病理分级的相关性研究

目的 了解YKL-40与前列腺癌的发生、发展及转移的关系,旨在探讨YKL-40作为肿瘤标记物用于前列腺癌早期诊断、病情监测的价值.方法收集新诊断且未经治疗的前列腺癌患者血液标本40例,前列腺增生患者血液标本21例,健康对照组患者血液标本19例,采用酶联免疫吸附（ELISA）双抗体夹心法分别检测其血清YKL-40浓度.结果前列腺癌患者组、前列腺增生患者组和健康对照组的血清YKL-40浓度分别为（167.74±59.61） ng/ml,（118.84±25.81） ng/ml,（72.29±15.00） ng/ml,血清YKL-40浓度与临床分期有相关性（P＜0.01）,且在前列腺癌患者转移阶段呈高度表达,与Gleason评分无相关性.YKL-40截断点为120.89 ng/ml时,灵敏度为86.7％,特异度为71.4％.结论YKL-40在前列腺癌患者血清中的浓度显著高于前列腺增生患者和正常患者,提示检测YKL-40对前列腺癌诊断有一定的临床意义；血清YKL-40浓度对预测前列腺癌患者转移可能有重要的价值,可能参与了前列腺癌患者转移的过程.

Association of serum YKL-40 with pathologic stage and clinical stage of prostate cancer

Objective To understand the relationship between YKL-40 with the occurrence,development,transfer of prostate cancer（P Ca）,and to investigate the value of YKL-40 as a tumor marker for early diagnosis and condition monitoring of prostate cancer.Methods Serum level of YKL-40 was measured with ELISA in 40 men with PCa newly diagnosed but untreated,in 21 men with benign prostatic hyperplasia,and in 19 healthy men.Results Serum YKL-40 concentration in men with PCa and benign prostatic hyperplasia,and in controls were （167.74 ± 59.61） ng/ml,（118.84 ± 25.81） ng/ml,and（72.29 ± 15.00） ng/ml,respectively.There was statistically significant association between serum YKL-40 expression and clinical stage （P ＜ 0.01）,but no correlation with Gleason scores,and it was highly expressed in the transfer process of PCa.A cut-off serum YKL-40 value of 120.89 ng/ml produced 86.7％ sensitivity and 71.4％ specificity.Conclusion YKL-40 in prostate cancer patients were significantly higher than in the patients with benign prostatic hyperplasia and normal,it is an important indicator for diagnosis of patients with PCa.Serum YKL-40 concentration on prediction PCa patients transfer may have important value;It may be involved in the transfer process in patients with PCa.